The pursuit of small-molecule drug discovery is a multifaceted endeavor aimed at developing chemical entities that meet specific target product profiles for clinical trial progression. This intricate process relies on multiparameter medicinal chemistry optimization. It begins with identifying promising compounds during the initial hit stage, focusing on their molecular properties that enhance the likelihood of success. Following this, medicinal chemists engage in iterative property optimization, often in parallel, to refine leads and ultimately select viable drug candidates. Recent advancements in design technology, synthetic methods, and innovative mechanisms of action are paving the way for tackling previously elusive high-value drug targets.
Methodological Developments in Medicinal Chemistry
This collection aims to showcase the latest methodological advancements and case studies within small-molecule medicinal chemistry programs. Emphasizing the design, synthesis, and evaluation of small molecules, we particularly spotlight new modalities such as covalent ligands, proximity-based strategies like PROTACs (Proteolysis Targeting Chimeras), RIPTACs (Regulated Induced Proximity Targeting Chimeras), LYTACs (Lysosome Targeting Chimeras), and glue compounds, as well as cyclic peptides and RNA-targeting agents. These innovations are expected to broaden the horizons of small-molecule drug discovery, reflecting the vibrant developments occurring in the field of medicinal chemistry.
A Call for Collaboration
We extend an invitation to all members of small-molecule drug discovery teams, including drug hunters, medicinal chemists, chemical biologists, pharmacologists, organic and process chemists from both academia and industry. We encourage you to share your latest insights, findings, and breakthroughs. We believe that these contributions will significantly influence the field and foster progress within the global drug discovery community.
Notable Contributors to the Field
György M. Keserű, PhD
Dr. György M. Keserű, a leading figure in medicinal chemistry, earned his Ph.D. in Budapest, Hungary. He started his career at Sanofi, where he led a chemistry research lab. In 1999, he joined Gedeon Richter, becoming the Head of Discovery Chemistry in 2007. His notable contributions include the discovery of the antipsychotic Vraylar® (cariprazine), which has been successfully marketed since 2016 in the US and EU. Since 2015, he has led the Medicinal Chemistry Research Group at the Research Centre for Natural Sciences and recently took on the role of Head of the National Drug Discovery and Development Laboratory. Dr. Keserű has authored over 340 papers and more than ten books and book chapters, earning prestigious awards such as the Overton and Meyer Award from the European Federation of Medicinal Chemistry. He is also a Fellow of the Royal Society of Chemistry and a corresponding member of the Hungarian Academy of Sciences.
Marc Nazare, PhD
Dr. Marc Nazare received his Ph.D. in organic chemistry from the Karlsruhe Institute of Technology (KIT) in Germany, completing his studies in 1999 under the guidance of Prof. Herbert Waldmann, focusing on natural product total synthesis. He began his professional journey at Sanofi-Aventis in Frankfurt as a medicinal chemist and project leader, working on various projects involving kinases, GPCRs, proteases, and ion channels, spanning both early and late preclinical research stages. Dr. Nazare has played a crucial role in developing clinical drug candidates, including Factor Xa inhibitors and P2Y12 antagonists for thrombosis treatment. In 2013, he became a research group leader in medicinal chemistry at the Leibniz Research Institute for Molecular Pharmacology in Berlin. He is currently an honorary professor at the University of Bielefeld and has authored over 120 papers while co-inventing more than 60 patents.
The Future of Drug Discovery
As we look toward the future of small-molecule drug discovery, the integration of new technologies and methodologies is essential. The ongoing collaboration among researchers from diverse backgrounds will foster an environment ripe for innovation. This synergy can lead to breakthroughs that not only address unmet medical needs but also enhance our understanding of complex biological systems.
Key Takeaways
- Small-molecule drug discovery focuses on developing chemical entities that meet target product profiles for clinical trials.
- Recent advancements in medicinal chemistry include new modalities such as PROTACs, cyclic peptides, and RNA-targeting compounds.
-
Collaboration among drug discovery teams from academia and industry is vital for advancing the field.
-
Influential figures like Dr. György M. Keserű and Dr. Marc Nazare exemplify the dedication and innovation driving medicinal chemistry forward.
In summary, the landscape of small-molecule drug discovery is evolving rapidly, propelled by innovative methodologies and collaborative efforts. As we embrace these changes, the potential for significant advancements in medicine becomes increasingly tangible. The future holds promise for new therapies that can transform patient care and treatment outcomes.
Read more → www.nature.com